Hims & Hers Health (NYSE:HIMS) Stock Rating Reaffirmed by Piper Sandler

Piper Sandler reaffirmed their neutral rating on shares of Hims & Hers Health (NYSE:HIMS) in a report released on Tuesday morning, Benzinga reports. The brokerage currently has a $18.00 price target on the stock.

Other equities analysts have also recently issued research reports about the stock. Bank of America raised their price target on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company a buy rating in a research report on Thursday, June 13th. Deutsche Bank Aktiengesellschaft increased their price target on Hims & Hers Health from $14.00 to $16.00 and gave the company a hold rating in a research report on Tuesday, May 7th. Canaccord Genuity Group raised their price objective on Hims & Hers Health from $20.00 to $24.00 and gave the company a buy rating in a research note on Wednesday, May 22nd. Seaport Res Ptn reiterated a buy rating on shares of Hims & Hers Health in a report on Friday, April 26th. Finally, Truist Financial boosted their price target on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a hold rating in a report on Thursday, July 18th. Eight equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of Hold and an average price target of $20.00.

Hims & Hers Health Stock Up 0.7 %

NYSE:HIMS traded up $0.11 on Tuesday, hitting $15.96. The stock had a trading volume of 8,244,545 shares, compared to its average volume of 7,900,966. The company has a market cap of $3.43 billion, a PE ratio of -1,596.00 and a beta of 1.08. Hims & Hers Health has a 52 week low of $5.65 and a 52 week high of $25.74. The business’s fifty day moving average is $21.12 and its 200 day moving average is $15.91.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a negative net margin of 0.24% and a negative return on equity of 0.70%. The business had revenue of $315.65 million during the quarter, compared to the consensus estimate of $302.43 million. During the same quarter last year, the firm posted ($0.03) EPS. Hims & Hers Health’s revenue was up 51.8% compared to the same quarter last year. Equities analysts predict that Hims & Hers Health will post 0.2 earnings per share for the current fiscal year.

Insider Activity at Hims & Hers Health

In related news, insider Michael Chi sold 2,054 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $22.00, for a total transaction of $45,188.00. Following the sale, the insider now directly owns 185,326 shares in the company, valued at approximately $4,077,172. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Hims & Hers Health news, insider Soleil Boughton sold 2,334 shares of Hims & Hers Health stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $17.30, for a total transaction of $40,378.20. Following the completion of the transaction, the insider now owns 164,475 shares of the company’s stock, valued at approximately $2,845,417.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Michael Chi sold 2,054 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $22.00, for a total transaction of $45,188.00. Following the completion of the sale, the insider now directly owns 185,326 shares in the company, valued at $4,077,172. The disclosure for this sale can be found here. In the last three months, insiders have sold 980,907 shares of company stock worth $19,445,689. Company insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

Hedge funds and other institutional investors have recently bought and sold shares of the company. Victory Capital Management Inc. boosted its position in shares of Hims & Hers Health by 23.0% during the 4th quarter. Victory Capital Management Inc. now owns 18,348 shares of the company’s stock valued at $163,000 after acquiring an additional 3,429 shares during the last quarter. Diversify Advisory Services LLC purchased a new position in Hims & Hers Health in the 1st quarter worth approximately $701,000. Forerunner Ventures Management LLC bought a new position in shares of Hims & Hers Health in the 4th quarter worth $86,836,000. Sei Investments Co. raised its position in shares of Hims & Hers Health by 206.9% during the 1st quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock valued at $869,000 after buying an additional 37,890 shares in the last quarter. Finally, Quantbot Technologies LP lifted its holdings in shares of Hims & Hers Health by 3,444.9% during the 1st quarter. Quantbot Technologies LP now owns 214,677 shares of the company’s stock worth $3,321,000 after acquiring an additional 208,621 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.